Medical treatment of critical limb ischemia: Current state and future directions

Current Vascular Pharmacology

Volumn 9, Issue 6, 2011, Pages 658-676

  Mangiafico, Roberto A ^a   Mangiafico, Marco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk reduction; Critical limb ischemia; Limb salvage; Medical treatment; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CILOSTAZOL; CIPROSTENE; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NAFTIDROFURYL; PENTOXIFYLLINE; PHENPROCOUMON; PICOTAMIDE; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; TRANDOLAPRIL; UNINDEXED DRUG; VARENICLINE; VERAPAMIL; WARFARIN;

ANALGESIA; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CRITICAL LIMB ISCHEMIA; DEVELOPED COUNTRY; DIABETES MELLITUS; DIABETIC FOOT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; FOLLOW UP; GRAFT PATENCY; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; INTERMITTENT CLAUDICATION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; ISCHEMIC HEART DISEASE; ISCHEMIC ULCER; LEG REVASCULARIZATION; LEG ULCER; LIFE EXPECTANCY; LIMB AMPUTATION; LIMB ISCHEMIA; LIMB PAIN; LIPOPROTEIN BLOOD LEVEL; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REST PAIN; SALVAGE THERAPY; SMOKING CESSATION; SMOKING HABIT; SPINAL CORD STIMULATION; STROKE; SYSTEMATIC REVIEW (TOPIC); TOBACCO DEPENDENCE; TREATMENT INDICATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; WOUND CARE; WOUND HEALING;

AMPUTATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; ISCHEMIA; LIMB SALVAGE; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; QUALITY OF LIFE; RISK FACTORS; SURVIVAL;

EID: 80054107111     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111797484107     Document Type: Article

References (251)

1. Diehm C, Allenberg JR, Pittrow D, et al.; German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic vs. symptomatic peripheral artery disease. Circulation 2009; 120: 2053-61.
2. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-53.
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654.
4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl: S5-67.
5. TransAtlantic Inter-Society Consensus (TASC) Working Group. Management of peripheral arterial disease (PAD). Int Angiol 2000; 19 Suppl: 1-304.
6. Jamieson C. The definition of critical ischaemia of a limb. Br J Surg 1982; 69 Suppl: S1.
7. Suggested standards for reports dealing with lower extremity ischemia. Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1986; 4: 80-94.
8. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991; 84(4 Suppl): IV1-26.
9. Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta 1954; 21: 499-533.
10. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-38.
11. Hankey GJ Vascular disease of the heart, brain and limbs: new insights into a looming epidemic. Lancet 2005: 366: 1753-54.
12. Fagot-Campagna A, Bourdel-Marchasson I, Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 2005; 31 Spec No 2: 5S35-5S52.
13. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254-64.
14. Kröger K, Stang A, Kondratieva J, et al.; Heinz Nixdorf Recall Study Group. Prevalence of peripheral arterial disease - results of the Heinz Nixdorf Recall Study. Eur J Epidemiol 2006; 21: 279-85.
15. Jensen SA, Vatten LJ, Myhre HO. The prevalence of chronic critical lower limb ischemia in a population of 20,000 subjects 40-69 years of age. Eur J Vasc Endovasc Surg 2006; 32: 60-5.
16. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A populationbased study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007; 45: 1185-91.
17. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-49.
18. Haimovici H. Patterns of arteriosclerotic lesions of the lower extremity. Arch Surg 1967; 95: 918-33.
19. Mavor GE. The pattern of occlusion in atheroma of the lower limb arteries: the correlation of clinical and arteriographic findings. Br J Surg 1956; 43: 352-64.
20. Dormandy J, Heek L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999; 12: 142-7.
21. Mangiafico RA, Fiore CE. Pharmacotherapy for intermittent claudication: from consensus-based to evidence-based treatment. Vasc Disease Prevention 2004; 1: 1-15.
22. Chetter IC, Spark JI, Dolan P, Scott DJ, Kester RC. Quality of life analysis in patients with lower limb ischaemia: suggestions for European standardisation. Eur J Vasc Endovasc Surg 1997; 13: 597-604.
23. Nehler MR, McDermott MM, Treat-Jacobson D, Chetter I, Regensteiner JG. Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med 2003; 8: 115-26.
24. Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC; JUVENTAS Study Group; SMART Study Group. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg 2010; 52: 843-9.
25. Nguyen LL, Moneta GL, Conte MS, Bandyk DF, Clowes AW, Seely BL; PREVENT III Investigators. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. J Vasc Surg 2006; 44: 977-83.
26. Murphy TP. Medical outcomes studies in peripheral vascular disease. J Vasc Interv Radiol 1998; 9: 879-89.
27. Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg 2010; 51: 230-41.
28. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008; 47: 774-81.
29. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
32. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
33. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12: 209-15.
34. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
35. Cacoub PP, Abola MT, Baumgartner I, et al.; REACH Registry Investigators. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis 2009; 204: e86-92.
36. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005; 42: 456-64.
37. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1983; 1: 217-9.
38. Lassila R, Lepäntalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand 1988; 154: 635-40.
39. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987; 221: 253-60.
40. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42: 67-74.
41. Smith SC Jr, Allen J, Blair SN, et al.; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72.
42. Hobbs SD, Bradbury AW. Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur J Vasc Endovasc Surg 2003; 26: 341-7.
43. Kiernan TJ, Hynes BG, Ruggiero NJ, Yan BP, Jaff MR. Comprehensive evaluation and medical management of infrainguinal peripheral artery disease: when to treat, when not to treat. Tech Vasc Interv Radiol 2010; 13: 2-10.
44. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008; 35: 158-76.
45. Gratziou C. Review of current smoking cessation guidelines. European Respiratory Society Monograph 2008; 42 (Smoking Cessation): 35-43.
46. Mallin R. Smoking cessation: integration of behavioral and drug therapies. Am Fam Physician 2002; 65: 1107-14.
47. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 2003; 45: 429-41.
48. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 2001; 6: 1547-51.
49. Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008; 3: 45-53.
50. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24: 946-55.
51. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009; 31: 463-91.
52. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221-9.
53. Bhatt DL, Steg PG, Ohman EM, et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
54. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002; 112: 49-57.
55. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J; Heart Outcomes Prevention Evaluation (HOPE) Study. Bloodpressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130-1.
56. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-6.
57. Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil- SR/Trandolapril STudy. Hypertension 2010; 55: 48-53.
58. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
59. Rosendorff C, Black HR, Cannon CP, et al.; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention.Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-88.
60. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
61. Singer DR, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter? Eur J Vasc Endovasc Surg 2008; 35: 701-8.
62. Fogoros RN. Exacerbation of intermittent claudication by propranolol. N Engl J Med 1980; 302: 1089.
63. Gokal R, Dornan TL, Ledingham JG. Peripheral skin necrosis complicating beta-blockage. Br Med J 1979; 1: 721-2.
64. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.
65. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66-70.
66. Olin JW. Hypertension and peripheral arterial disease. Vasc Med 2005; 10: 241-6.
67. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-54.
68. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
69. Paraskevas KI, Mikhailidis DP, Veith FJ. Optimal statin type and dosage for vascular patients. J Vasc Surg 2011; 53: 837-44.
70. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139-43.
71. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with newly diagnosed type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
72. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
73. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
74. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
75. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
76. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
77. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
78. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
79. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
80. American Diabetes Association. Standard of medical care in diabetes-- 20 Diabetes Care 2010; 33 Suppl 1: S1-61.
81. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
82. Hiatt WR, Krantz MJ. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med 2006; 11: 55-60.
83. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404.
84. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res 1996; 82: 523-32.
85. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301: 1909-19.
86. Fowkes FG, Price JF, Stewart MC, et al.; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
87. Belch J, MacCuish A, Campbell I, et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
88. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
89. Fowkes FG, Murray GD, Butcher I, et al.; Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis. JAMA 2008; 300: 197-208.
90. Sobel M, Verhaeghe R; American College of Chest Physicians; American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 815S-843S.
91. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical amendments. Fed Regist 1999; 64: 49652-5.
92. Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost 2003; 9: 115-20.
93. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives vs. aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2009; (4): CD001246.
94. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999; 281: 806-10.
95. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993; 87: 1563-9.
96. Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-52.
97. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15: 117-25.
98. Bhatt DL, Fox KA, Hacke W, et al.; CHARISMA Investigators. Clopidogrel and aspirin vs. aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
99. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192-201.
100. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2001; (3): CD001999.
101. Anand S, Yusuf S, Xie C, et al.; Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-27.
102. Dörffler-Melly J, Koopman MM, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005; (1): CD002071.
103. Watson HR, Bergqvist D. Antithrombotic agents after peripheral transluminal angioplasty: a review of the studies, methods and evidence for their use. Eur J Vasc Endovasc Surg 2000; 19: 445-50.
104. Schneider E, Mahler F, Do DD, et al. Zur rezidivprophlaxe nach perkutanes transluminaler angioplastie (PTA): antikoagulation vs. Ticlopidin. Vasa 1987; 16: 355-6.
105. Pilger E, Lammer J, Bertuch H, et al. Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results. Circulation 1991; 83: 141-7.
106. Do DD, Mahler F. Low-dose aspirin combined with dipyridamole vs. anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology 1994; 193: 567-71.
107. Koppensteiner R, Spring S, Amann-Vesti BR, et al. Lowmolecular- weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. J Vasc Surg 2006; 44: 1247-53.
108. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Low-molecular weight heparin vs. aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994; 344: 914-8.
109. Jivegård L, Drott C, Gelin J, et al. Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. Eur J Vasc Endovasc Surg 2005; 29: 190-8.
110. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127: 1112-5.
111. Arfvidsson B, Lundgren F, Drott C, Scherstén T, Lundholm K. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159: 556-60.
112. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-51.
113. Johnson WC, Williford WO; Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413-21.
114. Dörffler-Melly J, Büller HR, Koopman MM, Prins MH. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003; (4): CD000536.
115. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28: 446-57.
116. Collaborative overview of randomised trials of antiplatelet therapy- -II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 159-68.
117. Tangelder MJ, Lawson JA, Algra A, Eikelboom BC. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 1999; 30: 701-9.
118. Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi BM, Cairols M, Diehm C, et al. Results of the randomized, placebocontrolled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-33.
119. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major non-cardiac vascular surgery. Circulation 2003; 107: 1848-51.
120. Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA.The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104: 264-8.
121. Schouten O, Boersma E, Hoeks SE, et al; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009; 361: 980-9.
122. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32: 286-93.
123. Fleisher LA, Beckman JA, Brown KA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Non-cardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for non-cardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Non-cardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: e418-99.
124. Fatourou EM, Paraskevas KI, Seifalian AM, Hamilton G, Mikhailidis DP. The role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother 2007; 8: 901-11.
125. Lippi G, Veraldi GF, Dorucci V, et al. Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery. Scand J Clin Lab Invest 1998; 58: 497-504.
126. Abbruzzese TA, Havens J, Belkin M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39: 1178-85.
127. Henke PK, Blackburn S, Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004; 39: 357-65.
128. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-94.
129. Poldermans D, Boersma E, Bax JJ, et al.; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001; 22: 1353-8.
130. Fleischmann KE, Beckman JA, Buller CE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120: 2123-51.
131. Sprengers RW, Moll FL, Verhaar MC. Stem cell therapy in PAD. Eur J Vasc Endovasc Surg 2010; 39 Suppl 1: S38-43.
132. Schanzer A, Conte MS. Critical limb ischemia. Curr Treat Options Cardiovasc Med 2010; 12: 214-29.
133. Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg 2006; 44: 108-14.
134. Chiriano J, Bianchi C, Teruya TH, Mills B, Bishop V, Abou- Zamzam AM Jr. Management of lower extremity wounds in patients with peripheral arterial disease: a stratified conservative approach. Ann Vasc Surg 2010; 24: 1110-6.
135. Makita S, Nakamura M, Ohhira A, Itoh S, Hiramori K. Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans. Cardiovasc Drugs Ther 1997; 11: 441-8.
136. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992; 43: 889-924.
137. Karetova D, Bultas J, Vondracek V, Aschermann M. Alprostadil: modes of actions in peripheral arterial occlusive disease. Am J Ther 1997; 4: 359-63.
138. Arosio E, Minuz P, Prior M, et al. Vascular adhesion molecule-1 and markers of platelet function before and after a treatment with iloprost or a supervised physical exercise program in patients with peripheral arterial disease. Life Sci 2001; 69: 421-33.
139. Pola R, Gaetani E, Flex A, et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004; 36: 363-70.
140. Di Stefano R, Barsotti MC, Melillo E, et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008; 100: 871-7.
141. Makino H, Aoki M, Hashiya N, et al. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. Hypertens Res 2004; 27: 85-91.
142. Di Renzo M, Pieragalli D, Meini S, et al. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 405-10.
143. Schrör K, Hohlfeld T. Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease. Vasa 2004; 33: 119-24.
144. Mangiafico RA, Malatino LS, Santonocito M, et al. Effects of a 4- week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication. Int J Clin Pharmacol Ther 1999; 37: 347-51.
145. Nizankowski R, Królikowski W, Bielatowicz J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thromb Res 1985; 37: 21-8.
146. Negus D, Irving JD, Friedgood A. Intra-arterial prostacyclin compared to Praxilene in the management of severe lower limb ischaemia: a double blind trial. J Cardiovasc Surg (Torino) 1987; 28: 196-9.
147. Eklund AE, Eriksson G, Olsson AG. A controlled study showing significant short term effect of prostaglandin E1 in healing of ischaemic ulcers of the lower limb in man. Prostaglandins Leukot Med 1982; 8: 265-71.
148. Schuler JJ, Flanigan DP, Holcroft JW, Ursprung JJ, Mohrland JS, Pyke J. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial. J Vasc Surg 1984; 1: 160-70.
149. Telles GS, Campbell WB, Wood RF, Collin J, Baird RN, Morris PJ.Prostaglandin E1 in severe lower limb ischaemia: a double-blind controlled trial. Br J Surg 1984; 71: 506-8.
150. Belch JJ, McKay A, McArdle B, et al. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet 1983; 1: 315-7.
151. Cronenwett JL, Zelenock GB, Whitehouse WM Jr, Lindenauer SM, Graham LM, Stanley JC. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Surgery 1986; 100: 369-75.
152. Böhme H, Brülisauer M, Härtel U, Bollinger A. Kontrellierte Studie zur Wirnsamkeit von I.A. PGE, Infusionen bei Peripherer Arterieller Verschlusskrankheit im Stadium III und IV. Vasa 1987; 20(suppl): 206-208.
153. Norgren L, Alwmark A, Angqvist KA, et al. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study. Eur J Vasc Surg 1990; 4: 463-7.
154. Sakaguchi S. Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. Int Angiol 1984; 3: 39-42.
155. Trübestein G, Diehm C, Gruss JD, Horsch S. Prostaglandin E1 in chronic arterial disease--a multicenter study. Vasa 1987; 17: 39-43.
156. Diehm C, Hibsch-Miller C, Stammler F. Intravenose prostaglandin E1-therapie bei patienten mit peripherer arterieller verschlusskrankheit (AVK) im Stadium III: Eine doppelblinde, placebokontrollierte studie. In. Heinrich H, Bohme H, Rogatti W, Eds, Prostaglandin E1-Wirkungen und therapeutische Wirksamheit. Heidelberg: Springer-Verlag 1988; pp. 133-143.
157. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999; 130: 412-21.
158. Trübestein G, von Bary S, Breddin K, et al. Intravenous prostaglandin E1 vs. pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study. Vasa Suppl 1989; 28: 44-9.
159. Balzer K, Bechara G, Bisler H, et al. Placebo-kontrollierte, doppelblinde Multicenterstudie zur Wirksamkeit von Iloprost bei der Behandlung ischämischer Ruheschmerzen von Patienten mit peripheren arterillen Durchblutungsstörungen. Vasa 1987: 20(Suppl): 379-81.
160. Diehm C, Abri O, Baitsch G, et al. Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebocontrolled multicenter study. Dtsch Med Wochenschr 1989; 114: 783-8.
161. Brock FE, Abri O, Baitsch G, et al. Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweiz Med Wochenschr 1990; 120: 1477-82.
162. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. U. K. Severe Limb Ischaemia Study Group. Eur J Vasc Surg 1991; 5: 511-6.
163. Guilmot J, Diot E, for the French Iloprost Study Group Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analoque of prostacyclin: results of a French Multicentre trial. Drug Invest 1991; 3: 351-9.
164. The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. The Ciprostene Study Group. J Clin Pharmacol 1991; 31: 81-7.
165. Two randomised and placebo-controlled studies of an oral prostacyclianalogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg 2000; 20: 358-62.
166. Brass EP, Anthony R, Dormandy J, et al.; Circulase investigators. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006; 43: 752-9.
167. Nehler MR, Brass EP, Anthony R, et al.; Circulase investigators Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg 2007; 45: 953-60.
168. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 2004; 33: 137-44.
169. Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine III and IV peripheral occlusive arterial disease. Int Angiol 1994; 13: 133-42.
170. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; (1): CD006544.
171. Rydén L, Standl E, Bartnik M, et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
172. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-21.
173. Mangiafico RA, Fiore CE. Current management of intermittent claudication: the role of pharmacological and non-pharmacological symptom-directed therapies. Curr Vasc Pharmacol 2009; 7: 394-413.
174. Intravenous pentoxifylline. The European Study Group. Eur J Vasc Endovasc Surg 1995; 9: 426-36.
175. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group. Int Angiol 1996; 15: 75-80.
176. Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 1996; 8: 299-322.
177. Barradas MA, Stansby G, Hamilton G, Mikhailidis DP.Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In Vivo 1993; 7: 543-8.
178. Barradas MA, Jagroop IA, Mikhailidis DP. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin Chim Acta 1994; 230: 157-67.
179. Smith FB, Bradbury AW, Fowkes FG. Intravenous naftidrofuryl for critical limb ischaemia. Cochrane Database Syst Rev 2000; (2): CD002070.
180. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4(Suppl): S14-9.
181. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; (1): CD003748.
182. Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP.Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011; 12: 647-55.
183. Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003; 171: 337-42.
184. Ikewaki K, Mochizuki K, Iwasaki M, Nishide R, Mochizuki S, Tada N. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. Metabolism 2002; 51: 1348-54.
185. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 2011; 62: 15-7.
186. Shalhoub J, Davies AH, Franklin IJ. Cilostazol may improve outcome in critical limb ischemia. Int Angiol 2009; 28: 363-6.
187. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-9.
188. Stiegler H, Hess H, Mietaschk A, Trampisch HJ, Ingrisch H. Effect of ticlopidine on peripheral obliterating arteriopathy. Dtsch Med Wochenschr 1984; 109: 1240-3.
189. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double- blind study vs. placebo. Angiology 1982; 33: 357-67.
190. Kalani M, Apelqvist J, Blombäck M, et al. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2575-80.
191. Gauthier O. Efficacy and safety of CY216 in the treatment of specific leg ulcers. In: Breddin K, Fareed J, Samama M, Eds, Fraxiparine. Analytic and Structural Data, Pharmacology, Clinical Trials. Stuttgart: Schattauer 1987; p. 21.
192. Bell WR Jr. Defibrinogenating enzymes. Drugs 1997; 54 Suppl 3: 18-30.
193. Lowe GD, Morrice JJ, Forbes CD, Prentice CR, Fulton AJ, Barbenel JC. Subcutaneous ancrod therapy in peripheral arterial disease: improvement in blood viscosity and nutritional blood flow. Angiology 1979; 30: 594-9.
194. Dormandy JA, Goyle KB, Reid HL. Treatment of severe intermittent claudication by controlled defibrination. Lancet 1977; 1: 625- 626.
195. Lowe GD, Dunlop DJ, Lawson DH, et al. Double-blind controlled clinical trial of ancrod for ischemic rest pain of the leg. Angiology 1982; 33: 46-50.
196. Tønnesen KH, Sager P, Gormsen J. Treatment of severe foot ischaemia by defibrination with ancrod: a randomized blind study. Scand J Clin Lab Invest 1978; 38: 431-5.
197. Ubbink DT, Vermeulen H. Spinal cord stimulation for nonreconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2005; (3): CD004001.
198. Klomp HM, Steyerberg EW, Habbema JD, van Urk H; ESES study group. What is the evidence on efficacy of spinal cord stimulation in (subgroups of) patients with critical limb ischemia? Ann Vasc Surg 2009; 23: 355-63.
199. Gersbach P, Hasdemir MG, Stevens RD, Nachbur B, Mahler F. Discriminative microcirculatory screening of patients with refractory limb ischaemia for dorsal column stimulation. Eur J Vasc Endovasc Surg 1997; 13: 464-71.
200. Ubbink DT, Jacobs JHM. Spinal cord stimulation in critical limb ischemia.In: Branchereau A, Jacobs M, Eds, Critical limb ischemia. Armonk, NY: Futura Publishing Company, Inc. 1999; pp. 75-84.
201. Labropoulos N, Leon LR Jr, Bhatti A, et al. Hemodynamic effects of intermittent pneumatic compression in patients with critical limb ischemia. J Vasc Surg 2005; 42: 710-6.
202. Delis KT, Nicolaides AN, Labropoulos N, Stansby G. The acute effects of intermittent pneumatic foot vs. calf vs. simultaneous foot and calf compression on popliteal artery hemodynamics: a comparative study. J Vasc Surg 2000; 32: 284-92.
203. Delis KT. The case for intermittent pneumatic compression of the lower extremity as a novel treatment in arterial claudication. Perspect Vasc Surg Endovasc Ther 2005; 17: 29-42.
204. Kavros SJ, Delis KT, Turner NS, et al. Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up. J Vasc Surg 2008; 47: 543-9.
205. van Bemmelen PS, Gitlitz DB, Faruqi RM, et al. Limb salvage using high-pressure intermittent compression arterial assist device in cases unsuitable for surgical revascularization. Arch Surg 2001; 136: 1280-5.
206. Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compression pump for non-healing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int Angiol 2002; 21: 360-6.
207. Louridas G, Saadia R, Spelay J, et al. The ArtAssist Device in chronic lower limb ischemia. A pilot study. Int Angiol 2002; 21: 28-35.
208. Sultan S, Esan O, Fahy A. Non-operative active management of critical limb ischemia: initial experience using a sequential compression biomechanical device for limb salvage. Vascular 2008; 16: 130-139.
209. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2004; (2): CD004123.
210. Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. PMR 2009; 1: 471-89.
211. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010; 33: 998-1003.
212. Daly MC, Faul J,Steinberg JS. Hyperbaric oxygen therapy as an adjunctive treatment for diabetic foot wounds: a comprehensive review with case studies. Wounds 2010; 22: 1-11.
213. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care 1996; 19: 1338-1343.
214. Wu SC, Marston W, Armstrong DG. Wound care: the role of advanced wound healing technologies. J Vasc Surg 2010; 52(3 suppl): 59S-66S.
215. Kavros SJ, Miller JL, Hanna SW. Treatment of ischemic wounds with non-contact, low-frequency ultrasound: the Mayo clinic experience, 2004-2006. Adv Skin Wound Care 2007; 20: 221-6.
216. Ramundo J, Gray M. Is ultrasonic mist therapy effective for debriding chronic wounds? J Wound Ostomy Continence Nurs 2008; 35: 579-83.
217. Venturi ML, Attinger CE, Mesbahi AN, Hess CL, Graw KS. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) Device: a review. Am J Clin Dermatol 2005; 6: 185-94.
218. Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008; (3): CD001898.
219. Vikatmaa P, Juutilainen V, Kuukasjärvi P, Malmivaara A. Negative pressure wound therapy: a systematic review on effectiveness and safety. Eur J Vasc Endovasc Surg 2008; 36: 438-48.
220. Slovut DP, Sullivan TM. Critical limb ischemia: medical and surgical management. Vasc Med 2008; 13: 281-91.
221. Sanni A, Hamid A, Dunning J. Is sympathectomy of benefit in critical leg ischaemia not amenable to revascularisation? Interact Cardiovasc Thorac Surg 2005; 4: 478-83.
222. Paraskevas KI, Mikhailidis DP. Angiogenesis: a promising treatment option for peripheral arterial disease. Curr Vasc Pharmacol 2008; 6: 78-80.
223. Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol 2007; 5: 195-209.
224. Jia L, Takahashi M, Yoshioka T, Morimoto H, Ise H, Ikeda U. Therapeutic potential of endothelial progenitor cells for cardiovascular diseases. Curr Vasc Pharmacol 2006; 4: 59-65.
225. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
226. Simovic D, Isner JM, Ropper AH, Pieczek A, Weinberg DH. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-8.
227. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of endstage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-6.
228. Nikol S, Baumgartner I, Van Belle E, et al.; TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16: 972-8.
229. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a doubleblind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58-65.
230. Morishita R, Makino H, Aoki M, et al. Phase I/IIa Clinical Trial of Therapeutic Angiogenesis Using Hepatocyte Growth Factor Gene Transfer to Treat Critical Limb Ischemia. Arterioscler Thromb Vasc Biol 2011; 31: 713-20.
231. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I doseescalation experience. Circulation 2007; 115: 1234-43.
232. Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-26.
233. Sprengers RW, Moll FL, Teraa M, Verhaar MC; JUVENTAS Study Group. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg 2010; 51: 1564-8.
234. Lenk K, Adams V, Lurz P, et al. Therapeutical potential of bloodderived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005; 26: 1903-9.
235. Chochola M, Pytlík R, Kobylka P, et al. Autologous intra-arterial infusion of bone marrow mononuclear cells in patients with critical leg ischemia. Int Angiol 2008; 27: 281-90.
236. Sprengers RW, Lips DJ, Moll FL, Verhaar MC. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg 2008; 247: 411-20.
237. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-52.
238. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
239. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006; 26: 2140-6.
240. Yamamoto K, Kondo T, Suzuki S, et al. Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol 2004; 24: e192-6.
241. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-55.
242. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3- kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
243. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
244. Gensch C, Clever YP, Werner C, Hanhoun M, Böhm M, Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007; 192: 67-74.
245. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005; 68: 299-306.
246. Honda A, Matsuura K, Fukushima N, Tsurumi Y, Kasanuki H, Hagiwara N. Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway. Atherosclerosis 2009; 205: 376-84.
247. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-90.
248. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2004; 18: 203-9.
249. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526-9.
250. Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64: 1648-52.
251. Wang CH, Ting MK, Verma S, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 2006; 152: 1051.e1-8.